Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants

Completed · Phase 3

Conditions studied: Anemia Associated With End Stage Renal Disease

In brief

The purpose of this study is to assess the safety and effectiveness of roxadustat dosing regimens among hemodialysis participants converted from erythropoiesis stimulating agent (ESA) therapy or who are ESA-naïve.

Key facts

Study ID
NCT04484857
Run by
Kyntra Bio
People needed
283
Starts
2020-07-22
Expected to finish
2021-09-17
Last updated by the study team
2022-07-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.